Abstract Library

#4543 Single-cell transcriptomic landscape indicates the potential role of immunotherapy in metastatic pancreatic angiosarcoma

Introduction: Pancreatic angiosarcoma is a rare and highly aggressive tumour originated from lymphatic or vascular endothelial cells, with poor prognosis and few effective treatments. However, little is known about its tumour microenvironment and the mechanisms of its progression.

Conference:

Presenting Author: Yang Y

Authors: Yang Y, Chen L, Liu M, Lin X, Peng S,

Keywords: pancreatic angiosarcoma, single-cell RNA sequencing, immunotherapy, PD-L1, CD86,

#4541 Prognosis analysis of metastatic rectal neuroendocrine tumour: Liver-directed trans arterial embolisation may play a pivotal role

Introduction: Rectal neuroendocrine tumour (rNET) is prone to metastasis, and distant metastasis is associated with worse prognosis. However, factors influencing the prognosis of metastatic rNET and the recommended treatments remain controversial.

Conference:

Presenting Author: Yang Y

Authors: Yang Y, Chen L, Liu M, Jiang Y, Lin Y,

Keywords: metastatic rectal neuroendocrine tumour, liver metastasis, trans arterial embolisation, inverse probability of treatment weighting, overall survival,

#4539 Single-nucleus profiling of the tumour microenvironment in SI-NET patients

Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are frequently present as multiple synchronous primary tumours in the small bowel. They are thought to arise from enterochromaffin (EC) cells in the gut, which account for less than 1% of the intestinal epithelium. Previously reported lack of shared somatic driver alterations in SI-NETs suggests that other, non-genetic mechanisms are likely involved in their tumorigenesis.

Conference:

Presenting Author: Mäkinen N

Authors: Mäkinen N, Kasai Y, Kim G, Thirlwell C, Nakakura E,

Keywords: small intestinal NET, tumour microenvironment, single-nucleus sequencing,

#4494 Efficacy and safety of surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Updated results from a single-arm, phase II study

Introduction: Limited options exist for advanced G2/G3 NETs. While combined anti-angiogenic and chemotherapy has shown improved effect, the efficacy of surufatinib combined with CAPTEM for NETs remains under-explored.

Conference:

Presenting Author: Wang W

Authors: Wang W, Liu Z, Yang X, Xue Z, Wei C,

Keywords: g2/g3 net, surufatinib, captem,

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,